Po Yu (jeff) Chen - 06 Feb 2024 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
Director
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Issuer symbol
ANRO
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
4
Filing time
07 Feb 2024, 16:35:35 UTC
Previous filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANRO Common Stock Conversion of derivative security +39,259 39,259 06 Feb 2024 Direct F1
transaction ANRO Common Stock Conversion of derivative security +8,450 +22% 47,709 06 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANRO Series B Preferred Stock Conversion of derivative security $0 -83,333 -100% $0.000000* 0 06 Feb 2024 Common Stock 39,259 Direct F1
transaction ANRO Series C Preferred Stock Conversion of derivative security $0 -18,794 -100% $0.000000* 0 06 Feb 2024 Common Stock 8,450 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.
F2 Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date.